Loading organizations...
§ Private Profile · Carlsbad, CA, USA
Online B2B marketplace connecting scientists and suppliers for life science research products and healthcare supplies.
Key people at Chemdex (NASDQ:CMDX), renamed Ventro.
Founded in September 1997 by David Perry, Chemdex operated an online B2B marketplace connecting scientists and suppliers to streamline the procurement of life science research products and chemicals. Backed by prominent investors including Genentech cofounder Robert Swanson, Kleiner Perkins Caufield and Byers, CMGI, and Warburg Pincus, the company raised $45 million in venture capital. In July 1999, the enterprise completed an initial public offering that raised over $112 million, giving the firm a market capitalization of $758 million. During the dotcom boom in February 2000, the stock reached a peak of $243 per share, despite reporting nearly $12 million in sales against $33 million in losses for 1999. After shutting down its core marketplaces and laying off 235 employees in December 2000, the business acquired NexPrise and changed its name before its assets were sold to Trubiquity.
Key people at Chemdex (NASDQ:CMDX), renamed Ventro.
Chemdex Corporation (NASDAQ: CMDX), later renamed Ventro Corporation, was a pioneering B2B e-commerce company that operated an online marketplace for life sciences products like laboratory chemicals, enzymes, and equipment, later expanding into other industries.[1] It served suppliers and buyers in biotech and related sectors, aiming to solve procurement inefficiencies through a digital platform during the dot-com era, but achieved explosive growth momentum with a peak $7 billion market cap despite minimal revenues—$29,000 in 1998 and $165,000 in Q1 1999.[1]
The company exemplified dot-com bubble hype, raising $45 million in VC from investors like Genentech founder Robert A. Swanson and Kleiner Perkins, followed by a $112.5 million IPO in July 1999 that saw shares surge 60% on day one to $25, fueling rapid acquisitions and a name change to Ventro in 2000 amid stock peaks over $100.[1]
Founded in September 1997 by David Perry, a mid-level oil refinery manager at Exxon, Chemdex's business plan placed second in a Harvard University competition, sparking its creation as a life sciences e-marketplace.[1] Perry's idea emerged from recognizing procurement bottlenecks in specialized industries, leading to the service launch in October 1998.[1]
Early traction was bolstered by high-profile VC funding in 1999, enabling the July IPO and aggressive expansion via acquisitions like Promedix.com ($340 million in stock) and SpecialityMD.com ($115 million), plus a Tenet Healthcare joint venture—pivotal moments that propelled its valuation skyward before the bubble burst.[1]
Chemdex rode the late-1990s dot-com wave, capitalizing on internet optimism for B2B marketplaces amid trends like e-commerce digitization of supply chains in niche sectors like biotech.[1] Timing was critical: its 1999 IPO and expansions aligned with market euphoria, where sky-high valuations ignored revenues, influencing the startup ecosystem by validating B2B platforms and fueling VC into similar ventures like PlasticsNet.com.[1][5]
Market forces like explosive internet adoption favored it, but it amplified bubble excesses—$7 billion cap on negligible sales—highlighting froth that later contributed to the 2000 crash, ultimately rebranding to NexPrise before fading, a cautionary tale for tech valuations.[1]
As a defunct dot-com relic, Chemdex/Ventro has no active future, having collapsed post-bubble without sustained operations or relevance today.[1] Trends like modern B2B platforms (e.g., Alibaba, Coupa) echo its vision but with real revenues and AI efficiencies, evolving its influence into historical lessons on hype versus fundamentals—tying back to its $7 billion peak as a stark reminder of market mania.[1]